# Oral Peptide Formats: Capsules, Troches and the Bioavailability Question > Four barriers stand between a capsule and the circulation. Knowing which one your study cares about decides whether an oral format makes sense at all. Web page: https://peptidemedixeu.com/en/learn/oral-peptides-capsules-troches/ · Peptide Medix EU · 3 min read · Updated: 2026-09-23 Oral peptide formats are studied despite, not because of, gut absorption, which is poor. They exist because certain research questions require the peptide only to arrive in the gut lumen, and because capsules and troches evade the enteral barrier by different means. Published work puts systemic [bioavailability for](https://peptidemedixeu.com/en/glossary/bioavailability/) unmodified peptides swallowed in solution at under 1%, so any design using an oral format must declare whether the question is local or systemic. This guide sets out what destroys peptides along the gastrointestinal tract, how enteric coatings, salt forms and [sublingual troches](https://peptidemedixeu.com/en/glossary/sublingual-troche/) alter that picture, and how to think about an oral research design. It describes laboratory reference material. ## The four barriers a capsule must pass 1. Acid in the stomach. At pH around 1.5-3.5, hydrolysis of the backbone is catalysed and secondary structure unravels. An acid-labile sequence can lose most of its integrity during an hour in the stomach. 2. Proteases in the lumen. Pepsin first, then trypsin, chymotrypsin and carboxypeptidases from the pancreas in the duodenum, all of which exist specifically to cut peptide bonds. To these enzymes a research peptide looks exactly like dietary protein. 3. Brush-border enzymes and the epithelium. Anything surviving the lumen encounters aminopeptidases anchored on the enterocyte surface, then has to traverse an epithelium whose tight junctions block hydrophilic molecules far smaller than peptides. 4. First pass through the liver. Material that is absorbed enters the portal vein and passes the liver before reaching systemic circulation. Stacked together, these explain why oral bioavailability for an unmodified peptide is measured in fractions of a percent. The [oral semaglutide](https://peptidemedixeu.com/en/learn/what-is-semaglutide/) tablet is the instructive exception: it needed a permeation enhancer, SNAC, co-formulated at roughly 100 times the peptide mass to reach a reported bioavailability of about 0.4-1%, and it is a prescription medicine, not a research preparation. ## Local questions versus systemic ones Several of the most requested oral research peptides are studied for what they do inside the gastrointestinal tract, not beyond it. [BPC-157 capsules](https://peptidemedixeu.com/en/products/bpc-157-capsules/) and KPV capsules make the point clearly. BPC-157 was first isolated as a fragment of a protein found in human gastric juice, and much of the rodent literature uses gastrointestinal mucosal models in which the lumen and its mucosal lining are the compartment under study. KPV, the C-terminal tripeptide of α-MSH, has been tested in colitis models where the epithelium itself is the tissue of interest. In those designs, poor systemic absorption is nearer to an advantage than a flaw, since it concentrates exposure where the question lies and reduces confounding systemic signal. A study asking whether a peptide acts on a tendon or a receptor in the brain cannot reason that way, and an oral format is simply the wrong instrument. The format comparison for a single molecule is worked through in [BPC-157 capsules vs BPC-157](https://peptidemedixeu.com/en/learn/bpc-157-capsules-vs-bpc-157/). ## Differences between the formats ### A troche is not a slow-release capsule Sublingual troches are made to dissolve against the mucosa beneath the tongue, where the epithelium is thin, non-keratinised and drained by veins feeding the systemic circulation rather than the portal vein, so the absorbed portion avoids hepatic first pass entirely. Two problems follow. The same molecular-weight ceiling seen with nasal delivery applies, with absorption falling steeply above roughly 1,000 Da; and saliva keeps washing dissolved material toward the oesophagus, so whatever is swallowed re-enters the gastrointestinal route and all its barriers. Oxytocin troches (1,007 Da) sit right on that ceiling, while [AOD-9604](https://peptidemedixeu.com/en/learn/what-is-aod-9604/) troches (1,815 Da) sit above it, and the published rationale there rests on local and buccal exposure rather than efficient systemic uptake. ## What a capsule figure really represents Imagine a protocol specifying a [capsule holding 500 mcg](https://peptidemedixeu.com/en/glossary/micrograms-vs-milligrams/) of peptide. 1. Systemic equivalent assuming 1% bioavailability: 500 mcg × 0.01 gives 5 mcg arriving intact in circulation. That, not the 500 mcg on the label, is the figure to set against a parenteral reference arm. 2. At 0.3%, closer to what unmodified peptides report without a permeation enhancer: 500 × 0.003 gives 1.5 mcg. 3. Luminal concentration for a local question: 500 mcg released into an estimated 250 mL of intestinal fluid gives 2 mcg/mL, roughly 1.4 µM for a 1,420 Da peptide like BPC-157. A cell culture experiment can be designed around that number. 4. Comparison with a vial: a 5 mg vial reconstituted to 2.5 mg/mL delivers 500 mcg in 0.2 mL of solution with virtually nothing lost to proteolysis, a 100- to 300-fold difference in systemic mass delivered for the same nominal quantity. Saying which of these four figures a protocol refers to eliminates most of the ambiguity that dogs oral peptide studies. ## Handling and storage - Capsules and troches are solid presentations containing excipients. They are not reconstituted and should not be opened and dissolved unless the study specifically requires it, because the coating or matrix forms part of the specification. - Keep them cool, dry and dark. Moisture is the chief threat: gelatin and HPMC shells soften and stick together, and troche bases soften above about 25 °C. - Avoid refrigerating capsules in an unsealed container, since condensation when they are taken out is worse than ambient storage in a desiccated jar. - Lot certificates for oral formats should give peptide content per unit as well as the peptide's purity; ask for both, as explained in how to read a COA. ## Frequent errors - Setting an oral label mass against a parenteral one. They are different quantities, separated by two to three orders of magnitude in systemic terms. - Believing enteric coating lifts systemic bioavailability. It increases the intact peptide reaching the intestine, but leaves the epithelial barrier and first-pass metabolism untouched. - Putting a large peptide in a troche and calling the design sublingual delivery when most of it is swallowed. - Opening capsules to reconstitute the contents. The fill contains excipients uncharacterised for solution work, so the resulting concentration is unknown; use a lyophilized vial whenever a solution of known concentration is needed. The whole oral range is in the peptide [capsules](https://peptidemedixeu.com/en/collections/oral-capsules/) and oral collection. ## Frequently asked questions ### How much of an oral peptide is absorbed? For unmodified peptides, typically under 1% and frequently too little to measure. Gastric acid, pepsin, pancreatic proteases, brush-border peptidases and hepatic first-pass metabolism act one after another. Oral semaglutide reaches about 0.4-1% only by pairing the peptide with a permeation enhancer at around 100 times its mass, and that is an approved prescription product rather than research material. ### Why sell oral capsules if absorption is so poor? Because several widely studied sequences are examined for activity within the gastrointestinal tract rather than beyond it. BPC-157 was identified as a fragment of a gastric-juice protein and most of its literature uses gut mucosal models, while KPV has been tested in colitis models. In those designs the lumen and epithelium are the compartment of interest, so limited systemic uptake is no drawback. ### Does enteric coating increase absorption? It increases survival rather than absorption. The coating holds together below roughly pH 5 and releases its contents in the duodenum, so more intact peptide reaches the intestine. Neither the epithelial barrier nor first-pass metabolism changes, so systemic bioavailability usually stays below 1%. ### What makes a troche different from a capsule? A troche dissolves against the thin, non-keratinised mucosa under the tongue, which drains into systemic rather than portal veins, so the absorbed fraction escapes hepatic first pass. Absorption still declines sharply beyond about 1,000 Da, and saliva steadily carries some of the material into the stomach, where the usual gastrointestinal barriers take over. ### What does an arginate salt capsule mean? The peptide is paired with arginine as its counter-ion rather than the usual acetate or trifluoroacetate. The stated reasoning is improved aqueous stability and better survival in gastric conditions. That affects luminal survival, not the epithelial barrier, so systemic bioavailability remains in the same low range. ### Can capsule contents be dissolved for use? Not for quantitative work. The fill contains excipients chosen for a solid oral dosage form rather than for solution chemistry, leaving concentration, pH and purity unknown. When a solution of defined concentration is required, begin with a lyophilized vial carrying a lot-matched certificate of analysis. ### What are the storage requirements for capsules and troches? Cool, dry, dark and sealed. Humidity causes the most trouble, softening gelatin and HPMC shells so they stick together, while troche bases soften above roughly 25 °C. Do not refrigerate them in an unsealed container, since condensation on removal is more harmful than ambient storage in a desiccated jar. --- For laboratory research use only. This page is provided for scientific and educational information. Materials referenced here are sold strictly for in-vitro laboratory research by qualified professionals — not for human or veterinary use, and nothing on this page is medical advice.